Immunoglobulin Market Size, Share, Outlook, and Opportunity Analysis, 2018-2026

SEATTLE - Sept. 17, 2020 - PRLog -- Geographically, global Immunoglobulin Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America accounted for the largest share in the immunoglobulin market, followed by Europe in 2016. This is attributed to increasing number of the U.S. Food and Drug Administration approval for immunoglobulin. For instance, in 2016, Shire plc. announced the launch of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] the first and only Subcutaneous 20% treatment option without proline available in the U.S. to treat adult and pediatric patients (two years of age and older) with primary immunodeficiency (PI).

Immunoglobulin are used in treatment of autoimmune diseases such as multiple sclerosis, Primary Humoral Immunodeficiency (PIDD), Immune Thrombocytopenia Purpura (ITP), and autoimmune haemolytic anemia. Furthermore, immunoglobulin have applications in various other field such as hematology, neurology, immunology, dermatology, ophthalmology, nephrology and rheumatology, which is driving growth of the immunoglobulin market

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/immunoglobulin-market-1712

Furthermore, increasing number of geriatric population, which is more prone to develop disease due to low antibody immune response of body is propelling the demand for immunoglobulin. However, high cost of treatment, long-term side-effects, stringent regulatory framework, and emergence of alternative therapies such recombinant products are expected to restrain growth of the immunoglobulin market.

Furthermore, several pharmaceutical and biotechnological companies from Asia Pacific are focusing on expanding in their products overall the globe. For instance, the South Korea's Green Cross in November 2017, stated that the company expects to launch its immunodeficiency drugs in U.S. market in 2018, as company is been working with US FDA to prepare additional production-related data on its drug IVIG-SN, human normal immunoglobulin G for intravenous administration

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1712

Immunoglobulin manufactures are involved in research and development to develop new immunoglobulin drug. For instance, GigaGen received US$ 3 million grant from the National Institutes of Health in January 2018, to develop novel antibody therapies to advance its next-generation plasma therapy for patients with immune deficiencies

Evolve Biologics, a division of Therapure Biopharma Inc. in May 2018, announced the start of phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or "IVIG"). The PlasmaCap IG is an investigational IVIG replacement therapy being studied in both adult and pediatric patients with Primary Immune Deficiency Diseases (PIDD). More such ongoing clinical trials are supporting growth of the immunoglobulin market.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1712